Ma Li, Bian Mei-Lu, Cheng Jiao-Ying, Xiao Wei, Hao Min, Zhu Juan, Chen Ying, Liu Jun
Department of Gynecology and Obstetrics, China-Japan Friendship Hospital, Beijing 100029, P.R. China.
Exp Ther Med. 2010 Jan;1(1):193-198. doi: 10.3892/etm_00000031. Epub 2010 Jan 1.
Hybrid capture II (HC-II) is the only technique that can be used in clinical human papillomavirus (HPV) DNA detection. However, there is controversy in regards to how to analyze and assess the viral load of high-risk (HR)-HPV by use of HC-II and the relation between viral load and cervical lesions. In this study, we analyzed the results of a sequential screening of outpatients at the Department of Obstetrics and Gynecology of the China-Japan Friendship Hospital, and we aimed to explore the relationship between HR-HPV viral load and the severity of cervical lesions, and to clarify the clinical significance of the titer of HR-HPV DNA determined by HC-II. Using HC-II, 2,761 women were screened for HR-HPV DNA combined with cytological testing using liquid-based cytology. All women with HR-HPV-positive results or abnormalities in cytology underwent a cervical biopsy through colposcopy. Cervical biopsies were taken in 1,051 women. The HR-HPV infection rate was 78.35% (76/97) in HPV-associated lesions, 87.33% (193/221) in cervical intraepithelial neoplasia (CIN) I, 94.74% (144/152) in CIN II, 100% (178/178) in CIN III and 100% (20/20) in invasive cervical cancer (ICC), respectively (P<0.05). Based on the criteria of histopathology, the sensitivity of HR-HPV DNA testing by HC-II for detecting high-grade cervical lesions was 97.71%, the specificity was 79.64%, the positive-predictive value was 41.06% and the negative-predictive value was 99.59%. The viral loads of HR-HPV DNA were 512.15±764.19 in HPV-associated lesions, 753.95±978.27 in CIN I, 871.08±1003.52 in CIN II, 603.40±740.25 in CIN III and 466.44±673.05 in ICC, respectively. In conclusion, the positive rate of HR-HPV increased significantly in accordance with the severity of cervical lesions. The viral loads of cervical inflammatory lesions were markedly lower than CINs and ICC. The viral loads of HR-HPV DNA tested by HC-II had no correlation with the grade of cervical lesions.
杂交捕获二代(HC-II)是唯一可用于临床人乳头瘤病毒(HPV)DNA检测的技术。然而,关于如何使用HC-II分析和评估高危(HR)-HPV的病毒载量以及病毒载量与宫颈病变之间的关系存在争议。在本研究中,我们分析了中日友好医院妇产科门诊患者的序贯筛查结果,并旨在探讨HR-HPV病毒载量与宫颈病变严重程度之间的关系,以及阐明由HC-II测定的HR-HPV DNA滴度的临床意义。使用HC-II对2761名女性进行HR-HPV DNA筛查,并结合液基细胞学进行细胞学检测。所有HR-HPV检测结果阳性或细胞学异常的女性均通过阴道镜进行宫颈活检。1051名女性接受了宫颈活检。HR-HPV感染率在HPV相关病变中为78.35%(76/97)、宫颈上皮内瘤变(CIN)I级中为87.33%(193/221)、CIN II级中为94.74%(144/152)、CIN III级中为100%(178/178)、浸润性宫颈癌(ICC)中为100%(20/20),差异有统计学意义(P<0.05)。按照组织病理学标准,HC-II检测HR-HPV DNA对高级别宫颈病变的敏感性为97.71%,特异性为79.64%,阳性预测值为41.06%,阴性预测值为99.59%。HR-HPV DNA的病毒载量在HPV相关病变中为512.15±764.19、CIN I级中为753.95±978.27、CIN II级中为871.08±1003.52、CIN III级中为603.40±740.25、ICC中为466.44±673.05。总之,HR-HPV阳性率随宫颈病变严重程度显著增加。宫颈炎性病变的病毒载量明显低于CIN和ICC。HC-II检测的HR-HPV DNA病毒载量与宫颈病变分级无关。